We have observed
10 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after December 05, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
RATIONAL DESIGN OF COMPONENTS OF THE OLIGO-SACCHARYLTRANSFERASE-CATALYSED ASPARAGINE-LINKED GLYCOSYLATION
TREATMENT OF DISEASE WITH POLY-N-ACETY GLUCOSAMINE NANOFIBERS
Multiplex detection of nucleic acids
COMPOSITIONS AND METHODS FOR ACCURATELY IDENTIFYING MUTATIONS
Tumor suppression using placental stem cells
ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS
Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
Use of tam receptor inhibitors as antimicrobials
ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO CD37 PROTEINS
DERIVATIVES OF DOLAPROINE-DOLAISOLEUINE PEPTIDES